関連する実験動画
Updated: Jun 9, 2026

10:49
Measuring RAN Peptide Toxicity in C. elegans
Published on: April 30, 2020
アタキシン-2 中間の長さのポリグルタミン拡張は,ALSのリスクの増加と関連しています
Andrew C Elden1, Hyung-Jun Kim, Michael P Hart
1Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Nature
|August 27, 2010
まとめ
アタキシン2 (ATXN2) 中間ポリグルタミン増幅は,アミオトロフィック横筋硬化症 (ALS) と関連しています. この発見は,ALSおよび関連する神経変性疾患の潜在的な治療標的として,ATXN2-TDP-43の相互作用を強調しています.
科学分野:
- 神経科学は神経科学である.
- 遺伝学 遺伝学とは
- 分子生物学は分子生物学である.
背景:
- アミオトロフィック横筋硬化症 (ALS) の病原性は十分に理解されていないが,TDP-43は病気に関与している.
- ポリグルタミンタンパク質であるアタキシン2 (ATXN2) は,脊髄小脳性アタキシア2型で変異を起こしています.
研究 の 目的:
- ALSの病原性におけるATXN2の役割を調査する.
- ATXN2ポリグルタミン重複の長さがALSリスクと関連しているかどうかを判断する.
主な方法:
- 細胞および動物モデルでのATXN2とTDP-43の相互作用を調査しました.
- 915人のALS患者のATXN2ポリグルタミンリピート長さを分析した.
- 患者の脊髄ニューロンにおけるATXN2およびTDP-43の局所化を調べました.
主要な成果:
- ATXN2とTDP-43はRNA依存複合体を形成する.
- ALS患者のニューロンで異常なATXN2局所化が観察されました.
- ATXN2における中間の長さのポリグルタミン膨張 (27-33回) は,ALSと有意に関連している.
結論:
- ATXN2は,ALSに対する一般的な感受性遺伝子である.
- TDP-43-ATXN2の相互作用は,ALSとTDP-43のタンパク質病変の潜在的治療標的を提示しています.
関連する概念動画
Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Alternative RNA Splicing
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Allosteric Proteins-ATCase
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
